{"count": 429, "results": [{"_id": "36187122", "pmid": 36187122, "pmcid": "PMC9524196", "title": "Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials", "journal": "Front Endocrinol (Lausanne)", "authors": ["Nabrdalik K", "Skonieczna-Żydecka K", "Irlik K", "Hendel M", "Kwiendacz H", "Łoniewski I", "Januszkiewicz K", "Gumprecht J", "Lip GYH"], "date": "2022-09-14T00:00:00Z", "doi": "10.3389/fendo.2022.975912", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "975912", "score": 50270.504, "text_hl": "Whether the duration of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment has an impact on the incidence of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@GI AEs@@@ is unknown, however, @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@GI AEs@@@ may improve over time. ", "citations": {"NLM": "Nabrdalik K, Skonieczna-Żydecka K, Irlik K, Hendel M, Kwiendacz H, Łoniewski I, Januszkiewicz K, Gumprecht J, Lip GYH. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials Front Endocrinol (Lausanne). 2022;13():975912. PMID: 36187122", "BibTeX": "@article{36187122, title={Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials}, author={Nabrdalik K and Skonieczna-Żydecka K and Irlik K and Hendel M and Kwiendacz H and Łoniewski I and Januszkiewicz K and Gumprecht J and Lip GYH}, journal={Front Endocrinol (Lausanne)}, volume={13}, pages={975912}}"}}, {"_id": "38048543", "pmid": 38048543, "pmcid": "PMC10834386", "title": "Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6", "journal": "Diabetes Care", "authors": ["Klein KR", "Clemmensen KKB", "Fong E", "Olsen S", "Abrahamsen T", "Lingvay I"], "date": "2023-12-04T00:00:00Z", "doi": "10.2337/dc23-1791", "meta_date_publication": "2023 Dec 4", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50270.27, "text_hl": "Among participants experiencing @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@gastrointestinal adverse events@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use did not increase study product discontinuation. ", "citations": {"NLM": "Klein KR, Clemmensen KKB, Fong E, Olsen S, Abrahamsen T, Lingvay I. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6 Diabetes Care. 2023 Dec 4;():. PMID: 38048543", "BibTeX": "@article{38048543, title={Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6}, author={Klein KR and Clemmensen KKB and Fong E and Olsen S and Abrahamsen T and Lingvay I}, journal={Diabetes Care}}"}}, {"_id": "35337110", "pmid": 35337110, "pmcid": "PMC8951049", "title": "Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia", "journal": "Pharmaceuticals (Basel)", "authors": ["Top WMC", "Kooy A", "Stehouwer CDA"], "date": "2022-03-04T00:00:00Z", "doi": "10.3390/ph15030312", "meta_date_publication": "2022 Mar 4", "meta_volume": "15", "meta_issue": "3", "meta_pages": "", "score": 50267.305, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@: A Narrative Review of Its Potential Benefits for @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@Cardiovascular Disease@@@, @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@Cancer@@@ and @DISEASE_Dementia @DISEASE_MESH:D003704 @@@Dementia@@@", "citations": {"NLM": "Top WMC, Kooy A, Stehouwer CDA. Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia Pharmaceuticals (Basel). 2022 Mar 4;15(3):. PMID: 35337110", "BibTeX": "@article{35337110, title={Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia}, author={Top WMC and Kooy A and Stehouwer CDA}, journal={Pharmaceuticals (Basel)}, volume={15}, number={3}}"}}, {"_id": "37051071", "pmid": 37051071, "pmcid": "PMC10084537", "title": "Metformin adherence and the risk of cardiovascular disease: a population-based cohort study", "journal": "Ther Adv Chronic Dis", "authors": ["Yu SF", "Hong CT", "Chen WT", "Chan L", "Chien LN"], "date": "2023-04-04T00:00:00Z", "doi": "10.1177/20406223231163115", "meta_date_publication": "2023", "meta_volume": "14", "meta_issue": "", "meta_pages": "20406223231163115", "score": 50266.78, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ adherence and the risk of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular disease@@@: a population-based cohort study", "citations": {"NLM": "Yu SF, Hong CT, Chen WT, Chan L, Chien LN. Metformin adherence and the risk of cardiovascular disease: a population-based cohort study Ther Adv Chronic Dis. 2023;14():20406223231163115. PMID: 37051071", "BibTeX": "@article{37051071, title={Metformin adherence and the risk of cardiovascular disease: a population-based cohort study}, author={Yu SF and Hong CT and Chen WT and Chan L and Chien LN}, journal={Ther Adv Chronic Dis}, volume={14}, pages={20406223231163115}}"}}, {"_id": "36077136", "pmid": 36077136, "pmcid": "PMC9456496", "title": "From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease", "journal": "Int J Mol Sci", "authors": ["Poznyak AV", "Litvinova L", "Poggio P", "Moschetta D", "Sukhorukov VN", "Orekhov AN"], "date": "2022-08-27T00:00:00Z", "doi": "10.3390/ijms23179738", "meta_date_publication": "2022 Aug 27", "meta_volume": "23", "meta_issue": "17", "meta_pages": "", "score": 50265.62, "text_hl": "From @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ to @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@Atherosclerosis@@@: Potential of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ for Management of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@Cardiovascular Disease@@@", "citations": {"NLM": "Poznyak AV, Litvinova L, Poggio P, Moschetta D, Sukhorukov VN, Orekhov AN. From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease Int J Mol Sci. 2022 Aug 27;23(17):. PMID: 36077136", "BibTeX": "@article{36077136, title={From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease}, author={Poznyak AV and Litvinova L and Poggio P and Moschetta D and Sukhorukov VN and Orekhov AN}, journal={Int J Mol Sci}, volume={23}, number={17}}"}}, {"_id": "35032305", "pmid": 35032305, "title": "Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases.", "journal": "Drugs", "authors": ["Li T", "Providencia R", "Jiang W", "Liu M", "Yu L", "Gu C", "Chang ACY", "Ma H"], "date": "2022-02-01T00:00:00Z", "doi": "10.1007/s40265-021-01665-0", "meta_date_publication": "2022 Feb", "meta_volume": "82", "meta_issue": "3", "meta_pages": "311-322", "score": 50264.473, "text_hl": "Association of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ with the Mortality and Incidence of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@Cardiovascular Events@@@ in @SPECIES_9606 @@@Patients@@@ with Pre-existing @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@Cardiovascular Diseases@@@.", "citations": {"NLM": "Li T, Providencia R, Jiang W, Liu M, Yu L, Gu C, Chang ACY, Ma H. Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases. Drugs. 2022 Feb;82(3):311-322. PMID: 35032305", "BibTeX": "@article{35032305, title={Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases.}, author={Li T and Providencia R and Jiang W and Liu M and Yu L and Gu C and Chang ACY and Ma H}, journal={Drugs}, volume={82}, number={3}, pages={311-322}}"}}, {"_id": "37307806", "pmid": 37307806, "title": "Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research.", "journal": "Cardiology", "authors": ["Li JZ", "Li YR"], "date": "2023-06-12T00:00:00Z", "doi": "10.1159/000531432", "meta_date_publication": "2023 Jun 12", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50264.465, "text_hl": "@<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@Cardiovascular Protection@@@ by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@: Latest Advances in Basic and Clinical Research.", "citations": {"NLM": "Li JZ, Li YR. Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research. Cardiology. 2023 Jun 12;():. PMID: 37307806", "BibTeX": "@article{37307806, title={Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research.}, author={Li JZ and Li YR}, journal={Cardiology}}"}}, {"_id": "34053175", "pmid": 34053175, "pmcid": "PMC8278091", "title": "Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo", "journal": "J Cell Mol Med", "authors": ["Jiao Z", "Chen Y", "Xie Y", "Li Y", "Li Z"], "date": "2021-07-01T00:00:00Z", "doi": "10.1111/jcmm.16677", "meta_date_publication": "2021 Jul", "meta_volume": "25", "meta_issue": "14", "meta_pages": "6733-6745", "score": 50263.906, "text_hl": "Consequently, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may be an important potential new treatment strategy for hyperuricaemia-related @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular disease@@@.", "citations": {"NLM": "Jiao Z, Chen Y, Xie Y, Li Y, Li Z. Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo J Cell Mol Med. 2021 Jul;25(14):6733-6745. PMID: 34053175", "BibTeX": "@article{34053175, title={Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo}, author={Jiao Z and Chen Y and Xie Y and Li Y and Li Z}, journal={J Cell Mol Med}, volume={25}, number={14}, pages={6733-6745}}"}}, {"_id": "32606866", "pmid": 32606866, "pmcid": "PMC7308180", "title": "Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes", "journal": "Diabetes Metab Syndr Obes", "authors": ["Schweighofer N", "Genser B", "Maerz W", "Kleber ME", "Trummer O", "Pieber TR", "Obermayer-Pietsch B"], "date": "2020-06-18T00:00:00Z", "doi": "10.2147/DMSO.S235663", "meta_date_publication": "2020", "meta_volume": "13", "meta_issue": "", "meta_pages": "2069-2080", "score": 50263.63, "text_hl": "Hazard ratios for @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular death@@@ per @GENE_SLC22A1 @GENE_6580 @@@OCT1@@@ genotype in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ users. ", "citations": {"NLM": "Schweighofer N, Genser B, Maerz W, Kleber ME, Trummer O, Pieber TR, Obermayer-Pietsch B. Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes Diabetes Metab Syndr Obes. 2020;13():2069-2080. PMID: 32606866", "BibTeX": "@article{32606866, title={Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes}, author={Schweighofer N and Genser B and Maerz W and Kleber ME and Trummer O and Pieber TR and Obermayer-Pietsch B}, journal={Diabetes Metab Syndr Obes}, volume={13}, pages={2069-2080}}"}}, {"_id": "34332584", "pmid": 34332584, "pmcid": "PMC8325864", "title": "Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin", "journal": "Cardiovasc Diabetol", "authors": ["Tanaka A", "Shimabukuro M", "Teragawa H", "Okada Y", "Takamura T", "Taguchi I", "Toyoda S", "Tomiyama H", "Ueda S", "Higashi Y", "Node K", "EMBLEM Investigators"], "date": "2021-07-31T00:00:00Z", "doi": "10.1186/s12933-021-01352-0", "meta_date_publication": "2021 Jul 31", "meta_volume": "20", "meta_issue": "1", "meta_pages": "160", "score": 50261.76, "text_hl": "Nonetheless, previous meta-analyses have reported heterogeneous and controversial effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@CVD@@@ and mortality, due mainly to a lack of good evidence obtained using current standards of care and trial methodology. ", "citations": {"NLM": "Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K, EMBLEM Investigators. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin Cardiovasc Diabetol. 2021 Jul 31;20(1):160. PMID: 34332584", "BibTeX": "@article{34332584, title={Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin}, author={Tanaka A and Shimabukuro M and Teragawa H and Okada Y and Takamura T and Taguchi I and Toyoda S and Tomiyama H and Ueda S and Higashi Y and Node K and EMBLEM Investigators}, journal={Cardiovasc Diabetol}, volume={20}, number={1}, pages={160}}"}}]}